Clinical management of BC is dependent on criteria such as tumor size, age, Estrogen (ER) and Progesterone (PR) expression, and the presence or absence of amplification and concurrent enhanced Human epidermal growth factor receptor 2 (HER2) expression. This evidence concerns the gene ERBB2 and neoplasm.